a hot biotech stock for your 2025 radar! ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
 |
| A message from Sideways Frequency |  With a grand $32.50 price target from Zack's SCR and record breaking revenues in 2024, 2025 could be another epic breakout year for BSEM!
BioStem Technologies (OTC: BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. This little-known biotech company has generated record revenues in 2024 and has been dubbed a company to watch by Zack's Small Cap Research! In Q3 2024, the company posted revenue of $82.6 million for the quarter, totaling $199 million for the first nine-months of 2024. Following BSEM's Q3 results, Zack's Small Cap Research increased its price target from $24.25 to $32.50! A recent study has confirmed that BSEM technology is superior and very helpful to patients. As more doctors turn to BioStem for treatments, resulting in increasing sales, 2025 could be another year of jaw dropping revenues. Especially as the company is anticipating to uplist to the NASDAQ! BioStem Technologies Inc. (OTC: BSEM) has additionally achieved another major milestone by wrapping up 2024 with a Letter of Intent (LOI) to acquire commercial-stage products and development technologies from ProgenaCare Global LLC, a pioneering medical device company leveraging cutting-edge advances in biomaterials to provide effective, affordable advanced wound care solutions. The acquisition of ProgenaMatrix and revyve Antimicrobial Wound Gel reflects the Company's continued commitment to building a diverse portfolio of complementary wound care products that enable BioStem to leverage its commercial infrastructure. See how an anticipated NASDAQ uplisting and strong quarterly results are positioning BSEM for another potential epic run in 2025!
This message is a PAID ADVERTISEMENT for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency. StockEarnings, Inc. has received a fixed fee of $5200 from Sideways Frequency for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between January 24, 2025 and January 30, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BioStem Technologies Inc. (OTC: BSEM) or Sideways Frequency. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts website for additional information about the relationship between Sideways Frequency and BioStem Technologies Inc. (OTC: BSEM).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
| | |
| |
No comments:
Post a Comment